SecBot SecBot
SC 13D/A ·Filed Nov 9, 2026

FATE

FATE THERAPEUTICS INC
NEUTRAL
Impact 2/10
Horizonimmediate Processed7d 6h ago SEC0000905148-26-004718
Activist stake amendment (position change)
Actionable Insight • Neutral

This is a routine administrative amendment with no change in position or intent. Monitor for any future 13D amendments that signal a change in strategy, such as increasing the blocker limit or engaging in transactions.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1
Entry
$1.77
T+0 close · Nov 9, 2026 · via day close
Latest settled
−9.32%
T+1 · $1.61 · next T+5 in 5h
Vs SPY
−10.64%
α at T+1
Latest observation
−32.00%
T+4 · FF3 residual α
  1. T+0 · Nov 10 $1.77entry
  2. T+1 · 6d ago −9.32%α −10.64% · $1.61
  3. T+4 · todayOpen
  4. T+5 · in 5h Pending
  5. T+20 · in 22d Pending
  6. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Redmile Group filed Amendment No. 11 to its Schedule 13D solely to add Redmile Capital Offshore II Master Fund, Ltd. as a reporting person after its beneficial ownership surpassed 5% due to a change in Fate Therapeutics' outstanding share count. No transactions were executed, the aggregate stake remains at 14.99% (19,164,572 shares deemed beneficially owned), and no new demands or changes in purpose were disclosed.

Key Financial Metrics

Stake
14.99%
Investor
Redmile Group, LLC

Key Facts

  • Redmile Group and related entities collectively own 19,164,572 shares of Fate Therapeutics, representing 14.99% of common stock.
  • Redmile Capital Offshore II Master Fund, Ltd. was added as a reporting person after its beneficial ownership crossed 5% due to a change in the issuer's outstanding share count.
  • No transactions were executed by the reporting persons since the prior filing (Amendment No. 10 on April 22, 2026).
  • The filing states the purpose is unchanged; no new demands, strategic review, or board representation requests were disclosed.
  • The stake is subject to beneficial ownership blockers limiting conversion/exercise to 14.99% (can be increased to 19.99% with 61 days' notice).

Financial Impact

No financial impact; stake unchanged at 14.99% of shares outstanding.

Risk Factors

  • Redmile holds significant convertible preferred stock and pre-funded warrants that, if converted/exercised, could increase dilution but are currently capped at 14.99% beneficial ownership.
  • The blocker can be raised to 19.99% with 61 days' notice, which would signal increased conviction or potential activism.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
61% bullish (18 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
SC 13D/A Filing (Primary)0000905148-26-004718
Document: 0000905148-26-004718-index-headers.html0000905148-26-004718
Document: 0000905148-26-004718-index.html0000905148-26-004718
Document: 0000905148-26-004718.txt0000905148-26-004718

Track record

21 reports on FATE

Performance horizon

4 of 8 bullish or bearish reports moved the stock their way by T+5. Best: +30.25% at T+5 after the Nov 5, 2026 report. 9 of 10 went positive at some point.

Filters
  1. Nov 13, 20264d ago EFFECT Bearish 5/10 Entry $1.28 Now $1.14 +10.94% settles Nov 20
  2. Nov 12, 20264d ago 424B5 Bearish 4/10 Entry $1.28 Now $1.14 +10.94% settles Nov 20
  3. Nov 9, 20267d ago SC 13D/A Neutral 2/10 Viewing Entry $1.77 Now $1.14 −35.59% settles Nov 17
  4. Nov 5, 202611d ago S-3 Neutral 3/10 Entry $1.84 to $1.28 Now $1.14 −37.87% ▼ −30.25% −32.84% vs SPY
  5. Nov 5, 202611d ago 424B5 Bearish 5/10 Entry $1.84 to $1.28 Now $1.14 +37.87% ▲ +30.25% +32.84% vs SPY
  6. Nov 5, 202611d ago 8-K Bearish 5/10 Entry $1.84 to $1.28 Now $1.14 +37.87% ▲ +30.25% +32.84% vs SPY
  7. Nov 5, 202611d ago 8-K Neutral 4/10 No price data
  8. Nov 5, 202611d ago Press Release Neutral 4/10 Entry $1.85 to $1.34 Now $1.14 −38.38% ▼ −27.57% −30.86% vs SPY
  9. Nov 4, 202612d ago Institutional Cluster Neutral 3/10 Entry $2.09 to $1.61 Now $1.14 −45.45% ▼ −23.21% −22.29% vs SPY
  10. Nov 3, 202613d ago 144 Neutral 2/10 Entry $2.04 to $1.77 Now $1.14 −44.12% ▼ −13.24% −12.65% vs SPY
Showing 10 of 21

US Market Status

Market Closed · Opens in 7h 24m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 9, 2026